173 related articles for article (PubMed ID: 38114289)
1. Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis.
Challa B; Esnakula AK
Histopathology; 2024 Apr; 84(5):765-775. PubMed ID: 38114289
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis.
Lieb S; Heni M; Rauschenberg S; Lange K; Feisthammel J; Bläker H; Wiegand J
Z Gastroenterol; 2023 Nov; 61(11):1500-1503. PubMed ID: 36736346
[TBL] [Abstract][Full Text] [Related]
4. Diverticular disease-associated chronic colitis.
Makapugay LM; Dean PJ
Am J Surg Pathol; 1996 Jan; 20(1):94-102. PubMed ID: 8540614
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and significance of inflammatory bowel disease-like morphologic features in collagenous and lymphocytic colitis.
Ayata G; Ithamukkala S; Sapp H; Shaz BH; Brien TP; Wang HH; Antonioli DA; Farraye FA; Odze RD
Am J Surg Pathol; 2002 Nov; 26(11):1414-23. PubMed ID: 12409717
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of focal active colitis.
Greenson JK; Stern RA; Carpenter SL; Barnett JL
Hum Pathol; 1997 Jun; 28(6):729-33. PubMed ID: 9191008
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
[TBL] [Abstract][Full Text] [Related]
8. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
9. Histologic changes in defunctioned rectums in patients with inflammatory bowel disease: a clinicopathologic study of 82 patients with long-term follow-up.
Asplund S; Gramlich T; Fazio V; Petras R
Dis Colon Rectum; 2002 Sep; 45(9):1206-13. PubMed ID: 12352238
[TBL] [Abstract][Full Text] [Related]
10. Immune-mediated colitis associated with ocrelizumab: A new safety risk.
Kim T; Brinker A; Croteau D; Lee PR; Baldassari LE; Stevens J; Hughes A; Tomaino J; deFonseka A; Altepeter T; Kortepeter CM
Mult Scler; 2023 Sep; 29(10):1275-1281. PubMed ID: 37706451
[TBL] [Abstract][Full Text] [Related]
11. Endometriosis of the intestinal tract: a study of 44 cases of a disease that may cause diverse challenges in clinical and pathologic evaluation.
Yantiss RK; Clement PB; Young RH
Am J Surg Pathol; 2001 Apr; 25(4):445-54. PubMed ID: 11257618
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
Houtchens M; Howard D
Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
[TBL] [Abstract][Full Text] [Related]
14. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
15. Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis.
Malloy R; Fernandes R; Begun J; An YK
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36517079
[TBL] [Abstract][Full Text] [Related]
16. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease.
Szewczuk MR; Depew WT
Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000
[TBL] [Abstract][Full Text] [Related]
17. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy.
Joo M; Odze RD
Am J Surg Pathol; 2010 May; 34(5):689-96. PubMed ID: 20410806
[TBL] [Abstract][Full Text] [Related]
18. Pointers and pitfalls of mycophenolate-associated colitis.
Lee S; de Boer WB; Subramaniam K; Kumarasinghe MP
J Clin Pathol; 2013 Jan; 66(1):8-11. PubMed ID: 23038687
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
20. Colonic Epithelial Surfactant Protein D Expression Correlates with Inflammation in Clinical Colonic Inflammatory Bowel Disease.
Nexoe AB; Pilecki B; Von Huth S; Husby S; Pedersen AA; Detlefsen S; Marcussen N; Moeller JB; Holmskov U; Sorensen GL
Inflamm Bowel Dis; 2019 Jul; 25(8):1349-1356. PubMed ID: 30753482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
